Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 615-625

  Raguin, Gilles ^a,b   Chêne, Geneviève ^c   Morand Joubert, Laurence ^d   Taburets, Anne Marie ^e   Droz, Cécile ^c   Le Tiec, Clotilde ^e   Clavel, François ^f   Girard, Pierre Marie ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c INSERM   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e BICÊTRE HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CD4 ANTIGEN; CHOLESTEROL; CREATINE KINASE; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SENSITIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY; THRUSH; TREATMENT FAILURE; VIROLOGY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VOMITING;

ADULT; AGED; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SULFONAMIDES; VIRAL LOAD;

EID: 4344700528     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lucas GM, Chaisson RE & Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 131:81-87.
2. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftu R, Cohen PT & Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F44.
3. Montaner JS & Mellors JW. Antiretroviral therapy for previously treated patients. New England Journal of Medicine 2001; 345:452-455.
4. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C & Montaner JS. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
5. Leigh Brown AJ & Richman DD. HIV-1: gambling on the evolution of drug resistance. Nature Medicine 1997; 3:268-271.
6. Yeni P, Hammer SM, Carpenter CJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
7. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ & Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents & Chemotherapy 1998; 42:3218-3224.
8. Schmidt B, Korn K, Moschik B, Paatz C, Uberla K & Walter H. Low level of cross-resistance to amprenavir in samples from patients pretreated with other protease inhibitors. Antimicrobial Agents & Chemotherapy 2000; 44:3213-3216.
9. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y & Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001; 15:1009-1018.
10. Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, Rachlis A, Phillips E, Rubin G, Gough K & Walmsley S. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clinical Trials 2003; 4:301-310.
11. Khanlou H, Graham E, Brill M & Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002; 16:797-798.
12. Basso S, Solas C, Quinson AM, Ravaux I, Poizot-Martin I, Bacconier J, Durand A & Lacarelle B. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 31:115-117.
13. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E & Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhiitor-experienced patients. Journal of Virology 2001; 75:7262-7269.
14. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F & Fleury H. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrobial Agents & Chemotherapy 2002; 46:2926-2932.
15. Race E, Dam E, Obry V, Paulous S & Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
16. Jayewardene AL, Zhu F, Aweeka FT & Gambertoglio JG. Simple high performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. Journal of Chromatography 1998; B707:203-211.
17. Wiebolt R, McDonald E & McVey JM. Simultaneous Determination of Lopinavir and Ritonavir in Biological Samples using Reversed-phase High-performance Liquid Chromatography with either UV or Tandem Mass Spectrometric Quantitation. 2000. Abbott Park: Abbott Laboratories, Chicago, 2000.
18. Molla A, Vasavanonda S, Kuman G, Sham HL, Johnson M, Grabowski B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM, Norbeck DW & Kempf DJ. Human serum attenuates the activity of protease inhibitors towards wild-type and mutant human immunodeficiency virus. Virology 1998; 250:255-262.
19. Piantadosi S. Clinical Trials. A Methodologic Perspective. 1997. New York: John Wiley & Sons.
20. Montaner JS, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, Yip B, Harris M, Montessori V & O'Shaughnessy MV. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15:61-69.
21. Youle M, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, Story A, Mocroft A, Loveday C, Johnson MA & Phillips AN. Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. Journal of Acquired Immune Deficiency Syndromes 2002; 29:58-61.
22. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M & Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
23. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C & Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. Journal of Infectious Diseases 2000; 182:1375-1384.
24. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V & Mellors JW; AIDS clinical trials group 398 study team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Journal of the American Medical Association 2002; 288:169-180.
25. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
26. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 study team for the Terry Beirn community programs for clinical research on AIDS. AIDS 2000; 14:F83-93.
27. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR & Graham NM; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
28. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F & Girard PM; Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
29. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW & Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrobial Agents & Chemotherapy 1997; 41:654-660.
30. Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F & Girard PM, and the ANRS Protocol 104 (Puzzle 1) Investigators. Interactions between amprenavir and the lopinavir/ritonavir combination in heavily pretreated HIV-infected patients. Clinical Pharmacology & Therapeutics 2004; 75:310-323.
31. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G & Vilde JL. Amprenavir inhibitory quotient and virological response in human immuno-deficiency virus-infected patients on an amprenavir containing salvage regimen without or with ritonavir. Antimicrobial Agents & Chemotherapy 2002; 46:570-574.
32. Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, Demarles D, Gillotin C, Bidault R & Taburet AM. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents & Chemotherapy 2003; 47:118-123.
33. Sadler BM, Gillotin C, Lou Y & Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrobial Agents & Chemotherapy 2001; 45:30-37.
34. Bertz R, Lam W, Brun S, Kumar G, Fields C & Orth K. Multiple dose pharmacokinetics of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects (poster). 39th International Conference on Antimicrobial Agents & Chemotherapy, 26-29 September 1999, San Francisco, Calif., USA. Abstract 0327.
35. Tran JQ, Petersen C, Garrett M, Hee B & Kerr BM. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clinical Pharmacology & Therapeutics 2002; 72:615-626.
36. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.